Log in to save to my catalogue

Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, p...

Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, p...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1755539962

Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial

About this item

Full title

Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial

Publisher

England: Elsevier Ltd

Journal title

The Lancet (British edition), 2015-10, Vol.386 (10004), p.1649-1658

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background The thrombopoietin receptor agonist eltrombopag has been shown to be safe, tolerable, and effective for adults with chronic immune thrombocytopenia. We aimed to investigate the safety and efficacy of eltrombopag for children with chronic immune thrombocytopenia. Methods PETIT2 was a two part, randomised, multicentre, placebo-cont...

Alternative Titles

Full title

Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1755539962

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1755539962

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(15)61107-2

How to access this item